Get access

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

Authors

  • Giancarlo Comi MD,

    Corresponding author
    1. Institute of Experimental Neurology, Department of Neurology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy
    • Institute of Experimental Neurology, Department of Neurology, University Vita-Salute, Scientific Institute SanRaffaele, Via Olgettina 48, 20132 Milan, Italy
    Search for more papers by this author
  • Jeffrey A. Cohen MD,

    1. Mellen Center U-10, Cleveland Clinic Foundation, Cleveland, OH
    Search for more papers by this author
  • Douglas L. Arnold MD,

    1. McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, Montreal, Canada
    Search for more papers by this author
  • Daniel Wynn MD,

    1. Consultants in Neurology Multiple Sclerosis Center, Consultants in Neurology, Ltd, Northbrook, IL
    Search for more papers by this author
  • Massimo Filippi MD,

    1. Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Scientific Institute and University Hospital San Raffaele, Milan, Italy
    Search for more papers by this author
  • for the FORTE Study Group


Abstract

Objective:

To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40mg compared to a 20mg dose.

Methods:

Patients with multiple sclerosis (MS) with ≥1 documented relapse in 12 months prior to screening, or ≥2 documented relapses in 24 months prior to screening, and Expanded Disability Status Scale (EDSS) score 0 to 5.5 were enrolled. Patients were evaluated at screening, baseline, and at months 1, 2, 3, 6, 9, and 12. Primary endpoint was rate of confirmed relapses observed during 12-month study. Analysis was by intent-to-treat.

Results:

A total of 1,155 patients randomized to GA 20mg (n = 586) or 40mg (n = 569). The groups were well-matched at baseline on demographic, clinical, and magnetic resonance imaging (MRI) characteristics. The primary endpoint was similar in both groups (relative risk [RR] = 1.07; 95% confidence interval [CI], 0.88–1.31; p = 0.486) with mean annualized relapse rates (ARRs) of 0.33 for the 20mg group, 0.35 for the 40mg group, and 0.27 for patients from both groups who completed the entire 1-year treatment. A total of 77% of patients remained relapse-free in both groups. Both groups showed a reduction in mean number of gadolinium-enhancing and new T2 lesions over time with trend for faster reduction in the first trimester with the 40mg dose compared with 20mg dose. Both doses were well-tolerated with a safety profile similar to that observed in previous studies of 20mg GA.

Interpretation:

In relapsing-remitting MS patients, both the currently-approved GA 20mg and 40mg doses were safe and well-tolerated, with no gain in efficacy for the higher dose. Ann Neurol 2011;69:75–82.

Get access to the full text of this article

Ancillary